SOL vs. AIP, POET, AUDC, CAN, LAES, TBCH, IPAX, BKSY, ICG, and VLN
Should you be buying Emeren Group stock or one of its competitors? The main competitors of Emeren Group include Arteris (AIP), POET Technologies (POET), AudioCodes (AUDC), Canaan (CAN), SEALSQ (LAES), Turtle Beach (TBCH), Inflection Point Acquisition (IPAX), BlackSky Technology (BKSY), Intchains Group (ICG), and Valens Semiconductor (VLN). These companies are all part of the "electronic equipment" industry.
Emeren Group vs.
Arteris (NASDAQ:AIP) and Emeren Group (NYSE:SOL) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
In the previous week, Emeren Group had 4 more articles in the media than Arteris. MarketBeat recorded 9 mentions for Emeren Group and 5 mentions for Arteris. Arteris' average media sentiment score of 0.60 beat Emeren Group's score of 0.11 indicating that Arteris is being referred to more favorably in the media.
Emeren Group received 184 more outperform votes than Arteris when rated by MarketBeat users. However, 64.52% of users gave Arteris an outperform vote while only 45.43% of users gave Emeren Group an outperform vote.
Arteris has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Emeren Group has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.
Emeren Group has higher revenue and earnings than Arteris. Arteris is trading at a lower price-to-earnings ratio than Emeren Group, indicating that it is currently the more affordable of the two stocks.
Emeren Group has a net margin of -7.14% compared to Arteris' net margin of -58.27%. Emeren Group's return on equity of -2.05% beat Arteris' return on equity.
Arteris currently has a consensus price target of $12.75, indicating a potential upside of 84.25%. Emeren Group has a consensus price target of $4.13, indicating a potential upside of 163.58%. Given Emeren Group's higher probable upside, analysts clearly believe Emeren Group is more favorable than Arteris.
64.4% of Arteris shares are held by institutional investors. Comparatively, 44.1% of Emeren Group shares are held by institutional investors. 33.7% of Arteris shares are held by insiders. Comparatively, 37.3% of Emeren Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Emeren Group beats Arteris on 11 of the 18 factors compared between the two stocks.
Get Emeren Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emeren Group Competitors List
Related Companies and Tools
This page (NYSE:SOL) was last updated on 3/31/2025 by MarketBeat.com Staff
